Programming Cell Therapies to Overcome Solid Tumor Defense Systems

While CAR-T cell therapies have emerged as promising anti-cancer agents, their success have been focused on hematologic cancers. ArsenalBio is working to develop more robust cell therapies capable to treating a broader range of cancers by using synthetic biology to make them programable. We spoke to Ken Drazen, CEO of ArsenalBio, about the company’s next-generation T cell therapies, how it is able to program functions into these cells to overcome solid tumor defenses, and the company’s collaboration with Bristol-Myers Squibb announced at the start of the year.